Stockholm, July 6, 2011. Today, SLS Invest AB signed an agreement with Biolin Scientific AB, a subsidiary of Ratos AB, concerning the sale of SLS Invest’s 19.3 percent shareholding in Sophion Bioscience A/S. All remaining shareholders in Sophion has agreed to sell their shares at the same time. The sales price is DKK 155 million in total of which DKK 10 million depend on sales in 2011/12. The sale is expected to be concluded in Q3 2011.
Per Carendi, CEO of SLS Invest, comments:
"The sale of Sophion to Biolin Scientific will ensure the further development of Sophion's technology within electrophysiological recordings. We are pleased to have participated in bringing Sophion to the stage of increasing sales, profitability and positive cash flow. The sale is also an important step in restructuring SLS into an investment company where holdings of portfolio companies preferably exceed 50 percent."
SLS Invest will receive proceeds of approximately SEK 30 million for the sale of the...